- Home
- DPRO vs NXTC Comparison
DPRO vs NXTC Comparison
Compare DPRO & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DPRO
- NXTC
- Stock Information
- Founded
- DPRO 1998
- NXTC 2015
- Country
- DPRO Canada
- NXTC United States
- Employees
- DPRO N/A
- NXTC N/A
- Industry
- DPRO Aerospace
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- DPRO Industrials
- NXTC Health Care
- Exchange
- DPRO Nasdaq
- NXTC Nasdaq
- Market Cap
- DPRO 10.4M
- NXTC 13.9M
- IPO Year
- DPRO N/A
- NXTC 2019
- Fundamental
- Price
- DPRO $1.77
- NXTC $0.49
- Analyst Decision
- DPRO Strong Buy
- NXTC Strong Buy
- Analyst Count
- DPRO 2
- NXTC 2
- Target Price
- DPRO $6.00
- NXTC $3.50
- AVG Volume (30 Days)
- DPRO 247.4K
- NXTC 141.9K
- Earning Date
- DPRO 05-08-2025
- NXTC 05-01-2025
- Dividend Yield
- DPRO N/A
- NXTC N/A
- EPS Growth
- DPRO N/A
- NXTC N/A
- EPS
- DPRO N/A
- NXTC N/A
- Revenue
- DPRO $4,716,450.00
- NXTC N/A
- Revenue This Year
- DPRO $94.01
- NXTC N/A
- Revenue Next Year
- DPRO $95.14
- NXTC N/A
- P/E Ratio
- DPRO N/A
- NXTC N/A
- Revenue Growth
- DPRO 7.90
- NXTC N/A
- 52 Week Low
- DPRO $1.55
- NXTC $0.22
- 52 Week High
- DPRO $7.01
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- DPRO 39.67
- NXTC 55.20
- Support Level
- DPRO $1.63
- NXTC $0.45
- Resistance Level
- DPRO $1.93
- NXTC $0.52
- Average True Range (ATR)
- DPRO 0.11
- NXTC 0.05
- MACD
- DPRO 0.02
- NXTC 0.01
- Stochastic Oscillator
- DPRO 46.67
- NXTC 66.47
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.